



**Government of the District of Columbia
Department of Health**



**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002**

June 1, 2017

9:30am- 11:30 am

OPEN SESSION MINUTES

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

CALL TO ORDER: 9:40 am

PRESIDING: Dr. Daphne Bernard

BOARD MEMBERSHIP/ATTENDANCE:

BOARD MEMBERS:		
	DR .DAPHNE B. BERNARD, PHARM.D. R.PH CHAIRPERSON	Present
	MR. JAMES APPLEBY, R.PH VICE CHAIR	Absent
	DR. TAMARA MCCANTS, PHARM.D. R.PH	Present
	DR. BENJAMIN MILES PHARM.D. R.PH	Present
	MR. ALAN FRIEDMAN, R.PH	Present
	MR. EMMANUEL BELLEGARDE, CONSUMER MEMBER	Absent
	MR. EDDIE CURRY, CONSUMER MEMBER	Absent
STAFF:	SHAUNA WHITE-- EXECUTIVE DIRECTOR	
	KARIN BARRON-HEALTH LICENSING SPECIALIST	
	LAWRENCE HOLLAND, INVESTIGATOR	
LEGAL STAFF:	CARLA WILLIAMS, ASSISTANT GENERAL COUNSEL	
	ELLIOTT LAPARNE, LEGAL INTERN	
VISITORS:	Don Zowader, Public	
	Ashby Johnson, Howard University Pharmacy Student	
	Galin Tanashian, Howard University Pharmacy Student	
	Carolyn Price, President of the Washington DC Pharmacist Association	
	Charlene Fairfax, Senior Pharmacist with the Department of Health Care Finance	
	Kim Greenwood, Department of Health Immunization Program	
	Jennifer Thomas, Delmarva Foundation	
	Ryan Mouton, Safeway Pharmacy	

Open Session Agenda

Quorum: Yes

Introduction:		
o6o1-O-01	<p><u>Approval of the Open Session Meeting Minutes</u> May 4, 2017</p> <p>Motion: Board Member, Alan Friedman moved that the Board approve the May 4th open session meeting minutes. Seconded by: Board Member, Dr. Tamara McCants Motion Carried</p>	
<u>Consent Agenda</u>	None	
<u>Executive Director Report</u>	<p><u>Licensing Report</u></p> <p>Statistics</p> <p><u>Total Active Licensees:</u></p> <p>Pharmacy Technicians : 758 Pharmacy Technician Trainees: 165 Pharmacy Interns: 604 Pharmacists: 1,855 Pharmacists w/ the authority to immunize: 506 Pharmaceutical Detailers 1,140 Pharmacy Technician Trainee Programs: 7</p>	
<u>Assistant General Counsel Report</u>		Carla Williams
	None	
<u>Subcommittee Report</u>		Mr. Alan Friedman
	<p><u>Legislative and Regulatory</u></p> <p>Board Member, Alan Friedman reported that the Legislative and Regulatory Subcommittee met a month ago to address four topics. The topics were Naloxone, Board oversight over clinical lab technicians, Board oversight over Pharmaceutical Detailers, and an ongoing regulatory process.</p>	

Substance Abuse and Opioid Overdose Prevention Act of 2016:

Law 21-186 protects health care professionals from criminal or civil liability when prescribing or distributing an opioid antagonist to an overdose victim or a third party, unless the health professional's actions constituted recklessness, gross negligence, or intentional misconduct.

Board Member, Alan Friedman reported that in order to fulfil the requirement, the legislative and regulatory subcommittee plans to build a continuing education program and to invite stakeholders that are interested to be a part of the conversation.

**Clinical Laboratory Practitioners Amendment Act of 2014:
Board of Pharmacy Oversight over Clinical Laboratory Practitioners**

Board Member, Alan Friedman reported that the next steps are to establish an Advisory Committee on Clinical Laboratory Practitioners that shall develop and submit the Board of Pharmacy guidelines to regulate the practices of cytotechnology, histotechnology, and medical technology; to regulate the practices by cytotechnologists, histologic technicians, histotechnologists, medical laboratory technicians, medical technologists, and phlebotomists; and to establish the minimum qualifications for licensure of cytotechnologists, histologic technicians, histotechnologists, medical laboratory technicians, medical technologists, and registration of phlebotomists. There are currently five (5) vacancies available.

**Pharmaceutical Detailing Licensure Exemption Emergency
Amendment Act of 2016**

The act was amended by striking the phrase "30 consecutive days per calendar year" and inserting the phrase "30 days per calendar year". FAQ' regarding the amendment will be updated and the legislative subcommittee will address the impact of this amendment.

Ongoing Regulatory Review

Board Member, Alan Friedman reported that the subcommittee will be conducting regulatory review on the following regulations:

- District of Columbia Municipal Regulations for Pharmacists (Chapter 65)
- District of Columbia Municipal Regulations for Pharmacy Technicians (Chapter 99)
- District of Columbia Municipal Regulations for Pharmaceutical Detailers (Chapter 83)

The Pharmaceutical Control Division will inform the Legislative and Regulatory Subcommittee of changes to the District of Columbia Municipal Regulations for Pharmacies (Chapter 19) or to the Chapter 13 Prescription and Distributions regulations.

o601-O-02	<p>Notice of Proposed Rulemaking –Collaborative Practice Agreement Regulations</p> <p>During the February Board meeting the moved to approve the revised collaborative practice regulations as presented and to move forward with publication for consideration.</p>	Mr. Alan Friedman
o601-O-03	<p><u>Communications Subcommittee Report</u></p> <p>Dr. Bernard reported that content was submitted to be placed on the June 2017 newsletter. The newsletter will be published within the next few weeks.</p>	Dr. Daphne Bernard
o601-O-04	<p><u>DOH Pharmacy Intern Presentation</u> Pharmacy News</p> <p>Ashby Johnson and Galin Tanashian gave summary of the NABP E-Newsletter.</p>	Ashby Johnson and Galin Tanashian
NABP E-Newsletter	<p>May 18, 2017</p> <p>Safety of US Drug Supply Chain Threatened by Recent Congressional Importation Proposal, Indicates Former Director of FDA’s Office of Criminal Investigations</p> <p>DEA Reports Strong Turnout for 13th Prescription Drug Take-Back Day</p> <p>New, Dangerous Opioid Detected in Several States, Associated With Overdose Deaths</p> <p>C.O. Truxton Expands Recall to Include More Products as a Precaution to Initial Label Mix-up Error</p> <p>NACDS and HDA Oppose Prescription Drug Importation Proposal, Urge Congress to Protect Patients and Supply Chain</p> <p>A Former FBI Director Notes That Recent Drug Importation Proposal Increases Opportunity for Criminal Activity, Stress on Law Enforcement</p> <p>May 10, 2017</p> <p>FIP Report Shows Value of Pharmacists’ Role in Consumers’ Self-Care</p> <p>New CDC Guide Shows Link Between Physicians and Pharmacists Working Together to Improve Patient Outcomes</p> <p>Florida Governor Declares Public Health Emergency Due to Opioid Epidemic</p> <p>Utah Designates May ‘Talk To Your Pharmacist Month’ to Encourage Dialogue About Opioid Prescriptions</p>	

	<p>Omaha PDAC Open to Nebraska Pharmacists</p> <p>Seventeen Accrediting Organizations Join HPAC as New Members of the Collaborative</p> <p>New FDA Drug Info Rounds Training Video Discusses the Definition of a Drug</p>	
<u>Matters for Board Consideration</u>	None	
Comments from the Public		
Motion to Adjourn the Open Session	<p>Motion: Madam Chair, I Alan Friedman move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4);</p> <p>Seconded by: Board Member, Benjamin Miles</p> <p>Motion Carried</p> <p>(Roll Call Vote)</p>	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at 11:05 am